

August 29, 2025



Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

- *NeoGenomics wins summary judgment in patent infringement lawsuit against Natera; Court rules Natera’s patents are invalid for claiming ineligible subject matter*
- *NeoGenomics remains free to make, use, sell, and promote its RaDaR ST molecular residual disease (MRD) assay in the United States*

FORT MYERS, Fla.--(BUSINESS WIRE)-- [NeoGenomics, Inc.](https://www.neogenomics.com) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the District Court for the Middle District of North Carolina has granted NeoGenomics’ motion for summary judgment that all of Natera’s asserted patent claims are invalid for claiming ineligible subject matter. The Court stated that it will dismiss Natera’s claims against NeoGenomics with prejudice and enter declaratory judgment of invalidity of both of Natera’s asserted patents.

The order means that NeoGenomics remains free to broadly commercialize the RaDaR® ST assay, formerly RaDaR 1.1. NeoGenomics has launched RaDaR ST to biopharma customers and has submitted to the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MoIDX) for clinical reimbursement coverage for the RaDaR ST assay.

“We are pleased with the Court’s decision to invalidate Natera’s asserted patents. NeoGenomics is committed to providing cancer patients the most comprehensive array of diagnostic testing options to enable the highest quality of personalized care, which includes providing options for their MRD testing,” said Tony Zook, CEO of NeoGenomics. “We will continue to vigorously protect and defend our intellectual property to fuel the next wave of innovation and serve our patients.”

About NeoGenomics

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the U.S. and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

Forward Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20250829527926/en/>

Investor Contact

Kendra Webster

InvestorRelations@neogenomics.com

Media Contact

Andrea Sampson

asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.